Table 2. The available clinical characteristics of CESC cases and their relationship to overall survival.

Variables		Patient	Univariate analysis		Multivariate analysis
		N (289)	HR (95% CI)	P	HR (95% CI)	P
Race	White	199	1 [reference]
	Black	27	0.97 [0.46–2.05]	0.930
	Asian	27	1.06 [0.38–2.96]	0.910
	Others	2	7.39 [1–54.76]	0.050*
Age	<45	130	1 [reference]
	≥45	159	1.34 [0.82–2.18]	0.250
BMI	Lean	12	1 [reference]
	Normal	80	0.66 [0.23–1.95]	0.460
	Overweight	155	0.45 [0.16–1.3]	0.140
HPV	Low	265	1 [reference]
	High	2	3.38 [0.46–24.6]	0.230
Tobacco	Non-smoker	141	1 [reference]
	Current smoker	110	1.33 [0.81–2.18]	0.260
Clinical stage	Stage i	159	1 [reference]		1 [reference]
	Stage ii	68	0.81 [0.41–1.6]	0.550	1.66 [0.77–3.58]	0.196
	Stage iii	44	1.28 [0.63–2.58]	0.490	0.39 [0.39–4.53]	0.648
	Stage iv	18	4.41 [2.33–8.32]	<0.001*	3.70 [1.73–7.90]	<0.001*
T stage	t1+t2	206	1 [reference]
	t3+t4+tx	43	3.58 [2.01–6.35]	<0.001*
N stage	n0	130	1 [reference]
	n1	57	0.25 [0.13–0.5]	<0.001*
	nx	62	0.71 [0.36–1.38]	0.310
M stage	m0	112	1 [reference]
	m1	9	4.11 [1.38–12.23]	0.010*
	mx	124	1.93 [1.08–3.44]	0.030*
Neoplasm cancer	Tumor free	189	1 [reference]		1 [reference]
	With tumor	78	21.27 [11.11–40.72]	<0.001*	29.27 [12.54–68.30]	<0.001*
Menopause	Pre	121	1 [reference]
	Post	75	1.54 [0.54–4.43]	0.420
	Peri	25	1.65 [0.57–4.82]	0.360
RISK	Low	144	1 [reference]		1 [reference]
	High	145	2.48 [1.5–4.12]	<0.001*	2.60 [1.42–4.95]	0.002*

Note:

HR, hazard ratio; CI, confidence interval.

^*P < 0.05.